Selvita signs subsidiary merger plan. Market value for Selvita stock is PLN 357.9 million

Published on 10/15/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 sales fell to PLN 158.10 million from PLN 183.76 million. Selvita stock costs EUR 4.46 on October 15, 2026.

Leadership and operating metrics

Selvita signed a subsidiary merger plan on October 1, 2026.
First-half 2026 sales fell to PLN 158.10 million from PLN 183.76 million.
Selvita stock trades at EUR 4.46 at 1:17 p.m. CEST at Lang & Schwarz on October 15, 2026.

Selvita, PLSLVCR00029, Illustration mit AI erstellt.

Selvita (PLSLVCR00029) was trading at EUR 4.46 at Lang & Schwarz on October 15, 2026, while its market value stood at PLN 357.9 million. The company had agreed and signed a merger plan for subsidiaries on October 1, 2026, according to Agent Rynku.

Merger plan adds a corporate catalyst

The October 1 agreement concerns the planned merger of Selvita subsidiaries, placing the corporate structure alongside the strategic review that began in May 2026. The company has 18.36 million shares, according to onvista.

That development follows the appointment of Rafal Chwast as chief executive on September 18, 2026. Strefa Inwestorow reported that Chwast had more than 30 years of management experience and that Selvita was continuing its strategic review.

What do the first-half figures show?

Selvita reported PLN 158.10 million in sales for the first half of 2026, down from PLN 183.76 million a year earlier. EBITDA excluding the incentive scheme fell to PLN 23.88 million from PLN 30.91 million, according to BiznesRadar.

The operating picture was uneven. Drug Development commercial revenue rose 16.00 percent year over year to PLN 55.30 million in the first half, while its EBITDA increased 26.00 percent to PLN 16.10 million. The backlog for 2026 stood at PLN 306.00 million, compared with PLN 334.00 million a year earlier.

Three dated steps for Selvita

On September 17, 2026, the first-half report showed PLN 158.10 million in sales and PLN 23.88 million in adjusted EBITDA. On September 18, 2026, Selvita appointed a chief executive with more than 30 years of management experience. On October 1, 2026, the company signed a subsidiary merger plan, with 18.36 million shares reported in company market data.

When is the next reporting date?

The next quarterly report is expected on November 19, 2026, according to stockd. That date gives investors a scheduled point for judging whether the stronger Drug Development segment can offset pressure in Drug Discovery.

Stock valuation stays tied to execution

Selvita is listed on the Warsaw Stock Exchange and belongs to the sWIG80 index. Its current market value of PLN 357.9 million places the corporate changes beside a first-half revenue decline, making execution of the merger plan and the strategic review material for the next results update.

Trading price and next steps

The stock was trading at EUR 4.46 at Lang & Schwarz on October 15, 2026 at 1:17 p.m. CEST. The next scheduled reporting date is November 19, 2026, while the first-half figures and the subsidiary merger plan remain the key dated reference points for the company.

The further course of trading is shown by the continuously updated real-time quote of Selvita stock.